Response 445419961

Back to Response listing

About you

What is your name?

Full name (Required)
Dr. Phillip Altman

Which best describes your response? Please read the definition of "on behalf of an organisation" at the top of this page before responding.

Please select one item
(Required)
Radio button: Ticked I am responding as an individual
Radio button: Unticked I am responding on behalf of an organisation / institution

Individual

Which best describes you?

Please select one item
Radio button: Unticked Consumer / patient
Radio button: Unticked Registered healthcare professional
Radio button: Ticked Professional researcher
Radio button: Unticked None of the above / I am responding out of personal interest

Consultation Page

Please select the substance you would like to comment on:

Substance:
Please select one item
Radio button: Ticked Ivermectin
Radio button: Unticked Brimonidine
Radio button: Unticked Fexofenadine
Radio button: Unticked Ibuprofen
Radio button: Unticked Melatonin
Radio button: Unticked Green tea extract 
Radio button: Unticked Ethalfluralin
Radio button: Unticked Tigolaner
Please select one item
(Required)
Radio button: Ticked Fully support
Radio button: Unticked Partially support
Radio button: Unticked Oppose
Written response:
I have previously submitted 2 Open Letters to the National Covid Clinical Evidence Taskforce (dated 21 August 2021 and 14 October 2021). No response whatsoever was received. The submissions were ignored. These submissions are now re-submitted in the hope they will be considered due to national importance.